Michael Kurtz, DO
Sports Medicine · Garden Grove, CANPI 1194814020
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 895 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,852 and has fallen 58.7% since, to $1,592 in 2025.
Across 895 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Amgen$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Novo Nordisk$1K
- Johnson & Johnson$1K
- Pfizer$924
- plus $8K from 54 others
Across 111 payments — averaging $2206.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$55K
- Genentech, Inc.$47K
- Bristol Myers Squibb$40K
- Takeda Pharmaceuticals U.S.A., Inc.$31K
- Gilead$29K
- Bausch Health US, LLC$25K
- plus $19K from 2 others
What the payments were for
- Food & beverage$16,870100%
- Education$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,930 in reported general payments places this provider in the 75th percentile of 662 sports medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $51,465 |
| FarxigaDapagliflozin Propanediol | 39 | $43,711 |
| RybelsusSemaglutide | 23 | $41,105 |
| EliquisApixaban | 51 | $37,459 |
| VraylarCariprazine Hcl | 20 | $37,443 |
| JanumetSitagliptin Phos/Metformin Hcl | 27 | $35,859 |
| TrintellixVortioxetine Hydrobromide | 41 | $23,742 |
| JardianceEmpagliflozin | 30 | $23,739 |
| LinzessLinaclotide | 16 | $19,892 |
| Repatha SureclickEvolocumab | 21 | $13,972 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $13,147 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $9,944 |
| Np ThyroidThyroid,pork | 176 | $9,756 |
| Dexlansoprazole DrDexlansoprazole | 20 | $7,809 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $6,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,361 | $92,57175 claims |
| AbbVieVraylar, Linzess, Synthroid, Armour Thyroid | $2,620 | $65,179125 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $714 | $53,65651 claims |
| MerckJanumet, Janumet Xr | $98 | $42,62139 claims |
| PfizerEliquis | $924 | $37,45951 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $594 | $23,74241 claims |
| Boehringer IngelheimJardiance | $456 | $23,73930 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $117 | $18,75229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 662 sports medicine providers in California.
Other sports medicine in Garden Grove
- Neal ElattracheLos Angeles$51M
- Nathaniel CohenLos Gatos$6.4M
- Thomas KnappSanta Monica$2.5M
- Michael FreehillStanford$1.6M
- Allan MishraMenlo Park$1.5M
- Heinz Hoeneckela Jolla$1.4M
- Seth ShermanStanford$1.1M
- Stephan YacoubianBurbank$1M
- Stephen Snydervan Nuys$922K
- Deryk JonesSan Carlos$915K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.